Back to News
Market Impact: 0.25
Sunshine Biopharma Consensus Price Target Raised 1,900% to $1,142.40
Source: Nasdaq
Analyst EstimatesAnalyst Insights
Fintel-compiled analyst targets put Sunshine Biopharma’s average one-year price target at $1,142.40 per share, up 1,900.00% from the prior estimate of $57.12 dated October 20, 2026. The article provides no supporting rationale or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
SBFM0.40
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Apple reports after the bell. Options traders expect a big move
- Mizuho lowers Lumentum stock price target on Marvell acquisition
- Why is Apple stock falling afterhours today?
- RA Capital Management sells $9.13M in Lenz Therapeutics shares